Zie ook in gerelateerde artikelen

3 oktober 2022: Bron: 2019 Jul-Sep; 9(3): 115–121. Published online 2019 Sep 23

Ik ben vandaag eens op zoek gegaan naar studies met waterstoftherapie en kwam o.a. deze studie tegen waarbij 82 kankerpatiënten met vergevorderde kanker (stadium III en IV) zijn gevolgd nadat zij begonnen met waterstoftherapie via inhaleren. Met opmerkelijk goede resultaten:

Van de 58 patiënten waarbij een of meer abnormale tumormarkers verhoogd waren, waren de markers 13-45 dagen (mediaan 23 dagen) na inhalatie van waterstof bij 36,2% afgenomen. De grootste markerdaling was bij longkanker en de laagste bij alvleesklierkanker en levertumoren.

In Table 1 is te zien welke patiënten deelnamen aan deze studie. Na 4 weken behandeling waren cognitieve functie, pijn, eetlust, constipatie en diarree allemaal significant verbeterd, zie Table 2. Tijdens de studie follow-up zijn 12 patiënten overleden. Alle patiënten die overleden hadden kanker stadium IV.

Van de 80 patiënten met tumoren die zichtbaar waren op scans, was het totale ziektecontrolepercentage 57,5%, met een volledige en gedeeltelijke remissie die 21-80 dagen (mediaan 55 dagen) na waterstofinhalatie optrad. Het ziektecontrolepercentage was significant hoger bij stadium III-patiënten dan bij stadium IV-patiënten (respectievelijk 83,0% en 47,7%), met het laagste ziektecontrolepercentage bij patiënten met alvleesklierkanker.

Er werd geen hematologische toxiciteit waargenomen, hoewel in individuele gevallen kleine bijwerkingen werden waargenomen die spontaan verdwenen.

De fysieke fitheid van patiënten werd geëvalueerd met behulp van het Zubrod-ECOG-WHO-scoresysteem.
Na 3 maanden waterstofinhalatietherapie vertoonde 42% van de patiënten verbetering in fysieke conditie, 34% vertoonde stabiliteit en 24% vertoonde verslechtering. Het verbeteringspercentage bij patiënten die werden behandeld met alleen waterstofinhalatie was 32% en dat van patiënten die waterstofinhalatietherapie kregen in combinatie met andere behandelingen was 44%; en er was geen significant verschil tussen de twee groepen (P = 0.295).

Vergeleken met vóór de behandeling was het verbeteringspercentage van stadium III-patiënten 57% en dat van stadium IV-patiënten was 36%, zonder significant verschil tussen de groepen (P = 0,572). Er was variatie in de verbeteringen in fysieke fitheid bij patiënten met verschillende tumortypes. De grootste verbetering in fysieke fitheid werd waargenomen bij longkankerpatiënten (68%), terwijl alvleesklierkankerpatiënten (0%) en patiënten met gynaecologische tumoren (12%) de minste verbetering lieten zien. De verbetering van patiënten met longkanker was significant groter dan die van patiënten met gynaecologische- en pancreaskanker. Zie Table 3

Waterstoftherapie blijkt dus een goed effect te hebben bij kankerpatienten zonder noemenswaardige bijwerkingen. Bij mij zelf is een plekje huidkanker - basaal carcinoom op mijn schouder zonder enige behandeling van 1 cm doorsnede verdwenen. Er is alleen nog een heel klein rood stipje te zien ter grootte van een speldenprik. Of dat komt door de waterstoftherapie weet ik niet maar is wel opmerkelijk.

Hier een vertaling van het abstract van hierboven genoemde studie, abstract staat onderaan met referentielijst:

“Real world survey” of hydrogen-controlled cancer: a follow-up report of 82 advanced cancer patients

Een studie uitgevoerd in de praktijk bij 82 kankerpatiënten met vergevorderde kanker.

Abstract:

Geavanceerde kankerbehandeling is een enorme uitdaging en er zijn nieuwe ideeën en strategieën nodig. Waterstof oefent antioxiderende en ontstekingsremmende effecten uit die kunnen worden gebruikt om kanker onder controle te houden, waarvan het optreden en de progressie nauw verband houden met peroxidatie en ontsteking.

We voerden een prospectieve follow-upstudie uit bij 82 patiënten met stadium III en IV kanker die werden behandeld met waterstofinhalatie met behulp van de "real world evidence" -methode.
Na 3-46 maanden follow-up stierven 12 patiënten die kanker hadden in stadium IV. Na 4 weken waterstofinhalatie rapporteerden patiënten significante verbeteringen in vermoeidheid, slapeloosheid, anorexia en pijn. Bovendien had 41,5% van de patiënten een verbeterde fysieke toestand, waarbij het beste effect werd bereikt bij patiënten met longkanker en het slechtste bij patiënten met alvleesklierkanker en gynaecologische kankers.

Van de 58 patiënten waarbij een of meer abnormale tumormarkers verhoogd waren, waren de markers 13-45 dagen (mediaan 23 dagen) na inhalatie van waterstof bij 36,2% afgenomen. De grootste markerdaling was bij longkanker en de laagste bij pancreas- en levermaligniteiten.

Van de 80 patiënten met tumoren die zichtbaar waren op scans, was het totale ziektecontrolepercentage 57,5%, met een volledige en gedeeltelijke remissie die 21-80 dagen (mediaan 55 dagen) na waterstofinhalatie optrad. Het ziektecontrolepercentage was significant hoger bij stadium III-patiënten dan bij stadium IV-patiënten (respectievelijk 83,0% en 47,7%), met het laagste ziektecontrolepercentage bij patiënten met pancreaskanker.

Er werd geen hematologische toxiciteit waargenomen, hoewel in individuele gevallen kleine bijwerkingen werden waargenomen die spontaan verdwenen.

Conclusie:

Bij patiënten met gevorderde kanker kan geïnhaleerde waterstof de kwaliteit van leven van patiënten verbeteren en de progressie van kanker onder controle houden. Waterstofinhalatie is een eenvoudige, goedkope behandeling met weinig bijwerkingen die verder onderzoek rechtvaardigt als strategie voor klinische revalidatie van patiënten met gevorderde kanker.

2019 Jul-Sep; 9(3): 115–121.

Published online 2019 Sep 23. doi: 10.4103/2045-9912.266985

PMCID: PMC6779007

PMID: 31552873

“Real world survey” of hydrogen-controlled cancer: a follow-up report of 82 advanced cancer patients

Ji-Bing Chen,1,# Xiao-Feng Kong,2,# You-Yong Lv,3 Shu-Cun Qin,4 Xue-Jun Sun,5 Feng Mu,1 Tian-Yu Lu,1,2 and Ke-Cheng Xu, MD1,2*

Author information Article notes Copyright and License information Disclaimer

Abstract

Advanced cancer treatment is a huge challenge and new ideas and strategies are required. Hydrogen exerts antioxidant and anti-inflammatory effects that may be exploited to control cancer, the occurrence and progression of which is closely related to peroxidation and inflammation. We conducted a prospective follow-up study of 82 patients with stage III and IV cancer treated with hydrogen inhalation using the “real world evidence” method. After 3–46 months of follow-up, 12 patients died in stage IV. After 4 weeks of hydrogen inhalation, patients reported significant improvements in fatigue, insomnia, anorexia and pain. Furthermore, 41.5% of patients had improved physical status, with the best effect achieved in lung cancer patients and the poorest in patients with pancreatic and gynecologic cancers. Of the 58 cases with one or more abnormal tumor markers elevated, the markers were decreased at 13–45 days (median 23 days) after hydrogen inhalation in 36.2%. The greatest marker decrease was in achieved lung cancer and the lowest in pancreatic and hepatic malignancies. Of the 80 cases with tumors visible in imaging, the total disease control rate was 57.5%, with complete and partial remission appearing at 21–80 days (median 55 days) after hydrogen inhalation. The disease control rate was significantly higher in stage III patients than in stage IV patients (83.0% and 47.7%, respectively), with the lowest disease control rate in pancreatic cancer patients. No hematological toxicity was observed although minor adverse reactions that resolved spontaneously were seen in individual cases. In patients with advanced cancer, inhaled hydrogen can improve patients’ quality-of-life and control cancer progression. Hydrogen inhalation is a simple, low-cost treatment with few adverse reactions that warrants further investigation as a strategy for clinical rehabilitation of patients with advanced cancer. The study protocol received ethical approval from the Ethics Committee of Fuda Cancer Hospital of Jinan University on December 7, 2018 (approval number: Fuda20181207).

This follow-up observation study is the first to show that inhaling high concentrations hydrogen can improve quality-of-life and physical fitness and control cancer progression in patients with advanced cancer. To ensure therapeutic effectiveness, the inhaled hydrogen should be delivered at sufficiently high concentrations to rapid allow entry into tissues, and with enough time to produce a dose-accumulation effect. In this report, we emphasize the importance of rehabilitation and auxiliary intervention, rather than treatment in the general sense. However, more patients of each kind of cancers are required to validate this approach. Further investigations will also clarify issues such as the optimal treatment regimen (dose, duration, mode of delivery and effectiveness of hydrogen rehabilitation combined with mainstream treatment) and the mechanism by which of hydrogen treatment controls cancer (such as removal of reactive oxygen radicals and control of inflammation). This information is important for the development of effective hydrogen therapy for patients with advanced cancer.

Go to:

Footnotes

Conflicts of interest

There is no conflict of interest.

Financial support

None.

Institutional review board statement

The study protocol received ethical approval from the Ethics Committee of Fuda Cancer Hospital of Jinan University on December 7, 2018 (approval number: Fuda20181207) and conformed to the specifications of the World Medical Association’s Declaration of Helsinki. Written informed consent was obtained from each participant.

Informed consent statement

The authors certify that they have obtained all appropriate patient consent forms. In the form the patients or their legal guardians have given their consent for patients’ images and other clinical information to be reported in the journal. The patients or their legal guardians understand that their names and initials will not be published and due efforts will be made to conceal their identity.

Reporting statement

This study followed the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) Statement.

Copyright transfer agreement

The Copyright License Agreement has been signed by all authors before publication.

Data sharing statement

Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices). Study protocol and informed consent form will be available immediately following publication, without end date. Results will be disseminated through presentations at scientific meetings and/or by publication in a peer-reviewed journal. Anonymized trial data will be available indefinitely at www.figshare.com.

Plagiarism check

Checked twice by iThenticate.

Peer review

Externally peer reviewed.

Go to:

References

1. Siegel RL, Jemal A, Wender RC, Gansler T, Ma J, Brawley OW. An assessment of progress in cancer control. CA Cancer J Clin. 2018;68:329–339. [PubMed] [Google Scholar]

2. Neeman E, Ben-Eliyahu S. Surgery and stress promote cancer metastasis: new outlooks on perioperative mediating mechanisms and immune involvement. Brain Behav Immun. 2013;30(Suppl):S32–40. [PMC free article] [PubMed] [Google Scholar]

3. Karagiannis GS, Pastoriza JM, Wang Y, et al. Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism. Sci Transl Med. 2017;9:eaan0026. [PMC free article] [PubMed] [Google Scholar]

4. Zenitani M, Nojiri T, Hosoda H, et al. Chemotherapy can promote liver metastasis by enhancing metastatic niche formation in mice. J Surg Res. 2018;224:50–57. [PubMed] [Google Scholar]

5. Li T, Zeng ZC, Wang L, et al. Radiation enhances long-term metastasis potential of residual hepatocellular carcinoma in nude mice through TMPRSS4-induced epithelial-mesenchymal transition. Cancer Gene Ther. 2011;18:617–626. [PubMed] [Google Scholar]

6. Lapchak PA, Zhang JH. Data standardization and quality management. Transl Stroke Res. 2018;9:4–8. [PubMed] [Google Scholar]

7. Hodson R. Precision medicine. Nature. 2016;537:S49. [PubMed] [Google Scholar]

8. Tannock IF, Hickman JA. Limits to personalized cancer medicine. N Engl J Med. 2016;375:1289–1294. [PubMed] [Google Scholar]

9. Obenauf AC, Zou Y, Ji AL, et al. Therapy-induced tumour secretomes promote resistance and tumour progression. Nature. 2015;520:368–372. [PMC free article] [PubMed] [Google Scholar]

10. Sano M, Suzuki M, Homma K, et al. Promising novel therapy with hydrogen gas for emergency and critical care medicine. Acute Med Surg. 2018;5:113–118. [PMC free article] [PubMed] [Google Scholar]

11. Ge L, Yang M, Yang NN, Yin XX, Song WG. Molecular hydrogen: a preventive and therapeutic medical gas for various diseases. Oncotarget. 2017;8:102653–102673. [PMC free article] [PubMed] [Google Scholar]

12. Ohta S. Molecular hydrogen as a preventive and therapeutic medical gas: initiation, development and potential of hydrogen medicine. Pharmacol Ther. 2014;144:1–11. [PubMed] [Google Scholar]

13. Booth CM, Karim S, Mackillop WJ. Real-world data: towards achieving the achievable in cancer care. Nat Rev Clin Oncol. 2019;16:312–325. [PubMed] [Google Scholar]

14. Krause JH, Saver RS. Real-world evidence in the real world: beyond the FDA. Am J Law Med. 2018;44:161–179. [PubMed] [Google Scholar]

15. Xu H, Ping Y, Lin H, He P, Li W, Dai H. Antiplatelet strategies and outcomes in patients with noncardioembolic ischemic stroke from a real-world study with a five-year follow-up. Transl Stroke Res. 2017;8:228–233. [PubMed] [Google Scholar]

16. Clarke LP, Sriram RD, Schilling LB. Imaging as a biomarker: standards for change measurements in therapy workshop summary. Acad Radiol. 2008;15:501–530. [PubMed] [Google Scholar]

17. Bjordal K, de Graeff A, Fayers PM, et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. Eur J Cancer. 2000;36:1796–1807. [PubMed] [Google Scholar]

18. Girard R, Zeineddine HA, Fam MD, et al. Plasma biomarkers of inflammation reflect seizures and hemorrhagic activity of cerebral cavernous malformations. Transl Stroke Res. 2018;9:34–43. [PMC free article] [PubMed] [Google Scholar]

19. Dole M, Wilson FR, Fife WP. Hyperbaric hydrogen therapy: a possible treatment for cancer. Science. 1975;190:152–154. [PubMed] [Google Scholar]

20. Saitoh Y, Okayasu H, Xiao L, Harata Y, Miwa N. Neutral pH hydrogen-enriched electrolyzed water achieves tumor-preferential clonal growth inhibition over normal cells and tumor invasion inhibition concurrently with intracellular oxidant repression. Oncol Res. 2008;17:247–255. [PubMed] [Google Scholar]

21. Saitoh Y, Yoshimura Y, Nakano K, Miwa N. Platinum nanocolloid-supplemented hydrogendissolved water inhibits growth of human tongue carcinoma cells preferentially over normal cells. Exp Oncol. 2009;31:156–162. [PubMed] [Google Scholar]

22. Zhao L, Zhou C, Zhang J, et al. Hydrogen protects mice from radiation induced thymic lymphoma in BALB/c mice. Int J Biol Sci. 2011;7:297–300. [PMC free article] [PubMed] [Google Scholar]

23. Runtuwene J, Amitani H, Amitani M, Asakawa A, Cheng KC, Inui A. Hydrogen-water enhances 5-fluorouracil-induced inhibition of colon cancer. PeerJ. 2015;3:e859. [PMC free article] [PubMed] [Google Scholar]

24. Prasad V. Do cancer drugs improve survival or quality of life? BMJ. 2017;359:j4528. [PMC free article] [PubMed] [Google Scholar]

25. Prasad V, De Jesús K, Mailankody S. A further strategy to combat the high price of anticancer drugs. Nat Rev Clin Oncol. 2017;14:629. [PubMed] [Google Scholar]

26. Liang Y, Zhong Z, Huang Y, et al. Stem-like cancer cells are inducible by increasing genomic instability in cancer cells. J Biol Chem. 2010;285:4931–4940. [PMC free article] [PubMed] [Google Scholar]

27. Amelot A, Terrier LM, Mathon B, et al. Can anticancer chemotherapy promote the progression of brain metastases? Med Oncol. 2018;35:35. [PubMed] [Google Scholar]

28. Martin OA, Anderson RL. Editorial: Therapy-induced metastasis. Clin Exp Metastasis. 2018;35:219–221. [PubMed] [Google Scholar]

29. Ohsawa I, Ishikawa M, Takahashi K, et al. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat Med. 2007;13:688–694. [PubMed] [Google Scholar]

30. Yamamoto R, Homma K, Suzuki S, Sano M, Sasaki J. Hydrogen gas distribution in organs after inhalation: Real-time monitoring of tissue hydrogen concentration in rat. Sci Rep. 2019;9:1255. [PMC free article] [PubMed] [Google Scholar]

31. Kakkad S, Krishnamachary B, Jacob D, et al. Molecular and functional imaging insights into the role of hypoxia in cancer aggression. Cancer Metastasis Rev. 2019;38:51–64. [PMC free article] [PubMed] [Google Scholar]

32. Al Tameemi W, Dale TP, Al-Jumaily RMK, Forsyth NR. Hypoxia-modified cancer cell metabolism. Front Cell Dev Biol. 2019;7:4. [PMC free article] [PubMed] [Google Scholar]

33. Fujita K, Seike T, Yutsudo N, et al. Hydrogen in drinking water reduces dopaminergic neuronal loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. PLoS One. 2009;4:e7247. [PMC free article] [PubMed] [Google Scholar]

34. Ono H, Nishijima Y, Adachi N, et al. A basic study on molecular hydrogen (H2) inhalation in acute cerebral ischemia patients for safety check with physiological parameters and measurement of blood H2 level. Med Gas Res. 2012;2:21. [PMC free article] [PubMed] [Google Scholar]

35. Hanahan D. Rethinking the war on cancer. Lancet. 2014;383:558–563. [PubMed] [Google Scholar]

36. Haines I. The war on cancer: time for a new terminology. Lancet. 2014;383:1883. [PubMed] [Google Scholar]

37. Iida A, Nosaka N, Yumoto T, et al. The clinical application of hydrogen as a medical treatment. Med Okayama. 2016;70:331–337. [PubMed] [Google Scholar]

38. Akagi J, Baba H. Hydrogen gas restores exhausted CD8+ T cells in patients with advanced colorectal cancer to improve prognosis. Oncol Rep. 2019;41:301–311. [PubMed] [Google Scholar]

Articles from Medical Gas Research are provided here courtesy of Wolters Kluwer -- Medknow Publications

waterstoftherapie, waterstofbehandeling, kankerpatienten, bijwerkingen, coronavirus, chronische ziektes, reuma, atrose, COPD, longaandoeningen